Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.

[1]  D. Brough,et al.  Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. , 2000, The Journal of clinical investigation.

[2]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[3]  R. Martuza,et al.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.

[4]  E Marshall,et al.  Gene Therapy Death Prompts Review of Adenovirus Vector , 1999, Science.

[5]  T. Kijima,et al.  Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. , 1999, Cancer research.

[6]  F. Cosset,et al.  Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors , 1999, Gene Therapy.

[7]  Y. Chiang,et al.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. , 1999, Human gene therapy.

[8]  V. Schirrmacher,et al.  An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules , 1999, Cancer Gene Therapy.

[9]  S. Kenney,et al.  Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo. , 1999, Cancer research.

[10]  R. Samulski,et al.  Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody , 1999, Nature Biotechnology.

[11]  D. Meruelo,et al.  Cell‐specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant sindbis virus vector , 1999, International journal of cancer.

[12]  C. Miller,et al.  Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. , 1998, Cancer Research.

[13]  V. Schirrmacher,et al.  Immunization with virus-modified tumor cells. , 1998, Seminars in oncology.

[14]  K. Cichutek,et al.  Cell-Type-Specific Gene Transfer into Human Cells with Retroviral Vectors That Display Single-Chain Antibodies , 1998, Journal of Virology.

[15]  D. Stolz,et al.  Recombinant Herpes Simplex Virus Type 1 Engineered for Targeted Binding to Erythropoietin Receptor-Bearing Cells , 1998, Journal of Virology.

[16]  F. Goodrum,et al.  p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection , 1998, Journal of Virology.

[17]  C. Miller,et al.  An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism , 1998, Journal of Virology.

[18]  A. Hengstermann,et al.  Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells , 1998, Journal of Virology.

[19]  M. Coffey,et al.  Reovirus therapy of tumors with activated Ras pathway. , 1998, Science.

[20]  F. Cosset,et al.  In vivo selection of protease cleavage sites from retrovirus display libraries , 1998, Nature Biotechnology.

[21]  G F Pierce,et al.  Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Cortese,et al.  Targeted integration of adeno-associated virus-derived plasmids in transfected human cells. , 1998, Virology.

[23]  G. Yu,et al.  Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. , 1998, Human gene therapy.

[24]  M. Coffey,et al.  The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus , 1998, The EMBO journal.

[25]  J. Young,et al.  Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Chung,et al.  An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy , 1998, Nature Biotechnology.

[27]  B. Roizman,et al.  Herpes simplex viruses: is a vaccine tenable? , 2002, The Journal of clinical investigation.

[28]  J. Svoboda.  Molecular biology of cell nonpermissiveness to retroviruses. Has the time come? , 1998, Gene.

[29]  R. Hawkins,et al.  The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery , 1997, Gene Therapy.

[30]  D. Noël,et al.  Towards efficient cell targeting by recombinant retroviruses. , 1997, Molecular medicine today.

[31]  S. Efstathiou,et al.  The use of herpes simplex virus-based vectors for gene delivery to the nervous system. , 1997, Molecular medicine today.

[32]  D. Meruelo,et al.  Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A , 1997, Nature Biotechnology.

[33]  D. Curiel,et al.  Targeted adenoviral vectors for cancer gene therapy (Review). , 1997, International journal of oncology.

[34]  J. Simons,et al.  Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. , 1997, Cancer research.

[35]  R. Martuza,et al.  Transcriptional targeting of herpes simplex virus for cell-specific replication , 1997, Journal of virology.

[36]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[37]  Adrian L. Harris,et al.  Targeting gene expression to hypoxic tumor cells , 1997, Nature Medicine.

[38]  F. Cosset,et al.  A gene delivery system activatable by disease-associated matrix metalloproteinases. , 1997, Human gene therapy.

[39]  S. Karlsson,et al.  Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  F. Cosset,et al.  Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity. , 1996, Human gene therapy.

[41]  D. Brough,et al.  Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types , 1996, Nature Biotechnology.

[42]  D. Curiel,et al.  Targeted gene delivery by tropism-modified adenoviral vectors , 1996, Nature Biotechnology.

[43]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[44]  G. Karsenty,et al.  Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. , 1996, Cancer research.

[45]  J. Engler,et al.  Domains required for assembly of adenovirus type 2 fiber trimers , 1996, Journal of virology.

[46]  I. Kovesdi,et al.  Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies , 1996, Journal of virology.

[47]  D. Hallahan,et al.  Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature , 1996 .

[48]  L. J. Maher,et al.  Potential for H-DNA in the Human MUC1 Mucin Gene Promoter* , 1996, The Journal of Biological Chemistry.

[49]  F. Cosset,et al.  Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins , 1996, Journal of virology.

[50]  F. Cosset,et al.  Targeting of retroviral vectors through protease-substrate interactions. , 1996, Gene therapy.

[51]  B. Groner,et al.  Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles. , 1996, Gene therapy.

[52]  Erkki Ruoslahti,et al.  Organ targeting In vivo using phage display peptide libraries , 1996, Nature.

[53]  William J. Dower,et al.  Toward cell–targeting gene therapy vectors: Selection of cell–binding peptides from random peptide–presenting phage libraries , 1996, Nature Medicine.

[54]  A. Iwamoto,et al.  Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. , 1995, The Journal of general virology.

[55]  R. Martuza,et al.  Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. , 1995, Cancer research.

[56]  Y. Kan,et al.  Ligand-directed retroviral targeting of human breast cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  F. Cosset,et al.  Retroviral retargeting by envelopes expressing an N-terminal binding domain , 1995, Journal of virology.

[58]  R. Martuza,et al.  Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.

[59]  M. Zoppè,et al.  Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Samuel Hellman,et al.  Spatial and temporal control of gene therapy using ionizing radiation , 1995, Nature Medicine.

[61]  Y. Kan,et al.  Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. , 1994, Science.

[62]  I. Kawase,et al.  Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. , 1994, Cancer research.

[63]  J. Scharf,et al.  Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. , 1994, Gene therapy.

[64]  D. Hallahan,et al.  Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. , 1994, Cancer research.

[65]  J. Deisenhofer,et al.  Characterization of the knob domain of the adenovirus type 5 fiber protein expressed in Escherichia coli , 1994, Journal of virology.

[66]  R. Martuza,et al.  Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. , 1994, Cancer research.

[67]  G. Deléage,et al.  Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors , 1994, Journal of virology.

[68]  P. Kitts,et al.  Cell-binding domain of adenovirus serotype 2 fiber , 1994, Journal of virology.

[69]  K. Sikora,et al.  Gene therapy for cancer using tumour-specific prodrug activation. , 1994, Gene therapy.

[70]  A. Messing,et al.  GFAP promoter directs astrocyte-specific expression in transgenic mice , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[71]  Ari Helenius,et al.  Stepwise dismantling of adenovirus 2 during entry into cells , 1993, Cell.

[72]  D. Moscatelli,et al.  Expression of fibroblast growth factors and their receptors in acquired immunodeficiency syndrome—associated Kaposi sarcoma tissue and derived cells , 1993, Cancer.

[73]  T Friedmann,et al.  Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[74]  D. Tindall,et al.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.

[75]  H. Hurst,et al.  A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines. , 1993, The EMBO journal.

[76]  K. Sikora,et al.  Gene therapy for cancer. , 1992, Trends in biotechnology.

[77]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[78]  G. Winter,et al.  Retroviral vectors displaying functional antibody fragments. , 1993, Nucleic acids research.

[79]  R. Vile,et al.  In vitro and in vivo targeting of gene expression to melanoma cells. , 1993, Cancer research.

[80]  S. Carillo,et al.  The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. , 1992, The Journal of general virology.

[81]  L R Coney,et al.  Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. , 1992, Cancer research.

[82]  K. Sikora,et al.  Gene therapy for cancer , 1992, The Lancet.

[83]  T. Dale,et al.  High-level expression of the rat whey acidic protein gene is mediated by elements in the promoter and 3' untranslated region , 1992, Molecular and cellular biology.

[84]  E. Everitt,et al.  Infectious entry pathway of adenovirus type 2 , 1991, Journal of virology.

[85]  C. Richards,et al.  Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[86]  M. Klagsbrun,et al.  The fibroblast growth factor family. , 1991, Cancer cells.

[87]  D M Coen,et al.  Experimental therapy of human glioma by means of a genetically engineered virus mutant , 1991, Science.

[88]  C. Parrish.  Emergence, Natural History, and Variation of Canine, Mink, and Feline Parvoviruses , 1990, Advances in Virus Research.

[89]  B. Roizman,et al.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. , 1990, Science.

[90]  W. Ostertag,et al.  Vectors as Tools for the Study of Normal and Abnormal Growth and Differentiation , 1989, NATO ASI Series.

[91]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[92]  K. Tyler,et al.  Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Uematsu,et al.  Transcription of T cell receptor beta‐chain genes is controlled by a downstream regulatory element. , 1988, The EMBO journal.

[94]  J. Darnell,et al.  Cellular promoters incorporated into the adenovirus genome: cell specificity of albumin and immunoglobulin expression , 1986, Molecular and cellular biology.

[95]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[96]  T. Asada.  Treatment of human cancer with mumps virus , 1974, Cancer.

[97]  U. Pettersson,et al.  Virus-Receptor Interaction in an Adenovirus System , 1968, Journal of virology.

[98]  R. Huebner,et al.  Studies on the use of viruses in the treatment of carcinoma of the cervix , 1956 .

[99]  V. Schirrmacher,et al.  Modification of cancer vaccines by virus infection and attachment of bispecific antibodies. An effective alternative to somatic gene therapy. , 1998, Advances in experimental medicine and biology.

[100]  D. Curiel,et al.  Targeted adenoviral vectors for cancer gene therapy. , 1998, Advances in experimental medicine and biology.

[101]  J. Markert,et al.  Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins , 1998, Gene Therapy.

[102]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[103]  S. Russell.  Replicating vectors for gene therapy of cancer: risks, limitations and prospects. , 1994, European journal of cancer.

[104]  D. Curiel,et al.  Strategy for achieving selective killing of carcinomas. , 1994, Gene therapy.

[105]  R. Weiss.  Cellular Receptors and Viral Glycoproteins Involved in Retrovirus Entry , 1993 .

[106]  P. Roux,et al.  Cell Targeting by Recombinant Retroviruses Using Bi-Specific Antibody Complexes , 1989 .

[107]  W. Cavenee,et al.  Molecular mechanisms of oncogenesis. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[108]  J. O'Donohoe.  Has the Time Come , 1964 .